Purchase this article with an account.
Florian Sulzbacher, Stefan Sacu, Philipp Ken Roberts, Marion Ronit Munk, Maria Elisabeth Kroh, Alexandra Kaider, Sandra Rezar, Ursula Schmidt-Erfurth, Vienna Eye Study Center; Relationship of Retinal morphology and Sensitivity in Neovascular Age-related Macular Degeneration (NAMD). Comparision of Ranibizumab versus Aflibercept treatment over 1 year. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1521.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the OCT-related functional treatment response between Ranibizumab and Aflibercept treatment after 12 month in patients with neovascular age-related macular degeneration (nAMD).
Fourty four eyes showing untreated nAMD were examined with the Heidelberg Spectralis-OCT (SD-OCT) and the NIDEK MP-1 microperimetry (MP) at baseline, at month 3 and at month 12 receiving a fixed regimen of intravitral ranibizumab (22 eyes) or aflibercept injections (22 eyes).<br /> The fundusphoto (FP) of the MP was exactly matched with the infrared+OCT image of the SD-OCT using imaging processing software.<br /> Each test point of light sensitivity in the FP was transmitted to the corresponding location on SD-OCT and subsequently the microperimetric results were evaluated with respect to the following OCT-findings: neovascular complex (NVC), serous pigment epithelium detachment (sPED), fibrovascular PED (fPED), subretinal fluid (SRF), intraretinal fluid (IRF) and intraretinal cysts (IRC) at baseline and after 1 year.
From baseline to month 12, significant improvements in retinal sensitivity were observed for SRF and sPED, with median [quartile] values of 7dB [3dB, 12dB] / 10.5dB [3dB, 14.5dB] with Ranibizumab and 6dB [0dB, 9dB] / 6dB [5dB, 9dB] with Aflibercept treatment (p<0.0001 for both agents). From baseline to month 12 no significant change in median retinal sensitivity was observed for NVC, IRF, fPED, IRC neither with Ranibizumab treatment with median [quartile] values of 0.5dB [0dB, 5dB], 1dB [-2.5dB, 6dB], 0dB [-3dB, 6dB], -4dB [-8dB, -1dB] nor with Aflibercept treatment with 0dB [0dB, 0dB], 0dB [-2dB, 5dB], 3dB [-3dB, 8dB], 0dB [-5dB, 2dB], (p>0.1 for both agents).
After 1 year Ranibizumab and Aflibercept showed equal significant benefit for SRF and sPED whereas for NVC, fPED, IRF and IRC no significant benefit was registered for both agents.
This PDF is available to Subscribers Only